Having received antitrust clearance from US authorities, Galderma has completed the acquisition of Alastin Skincare®, Inc., a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The transaction was previously announced in November. 

In 2020 Alastin was named the fastest-growing brand in the professional skincare market in the US. Galderma says this acquisition will enhance its integrated dermatology platform with a comprehensive collection of scientifically-proven products for daily skincare regimens and peri-procedural use, and underscores the company’s commitment to be the partner of choice for aesthetic professionals. 

“I am so happy to officially welcome the Alastin team to Galderma. As a part of our integrated dermatology approach, we are continuously seeking to add products that synergize with our premium portfolio - and ALASTIN is the perfect fit,” sayd Flemming  Ørnskov, MD, MPH, CEO of Galderma.

“The Alastin brand’s proprietary and award-winning skincare technology, combined with Galderma’s world-class pipeline and innovation track record, represents an unparalleled opportunity for Galderma to better meet the needs of aesthetic professionals and patients, now and well into the future.”